Intima Capital is a New York-based global firm that seeks to capture superior, uncorrelated, risk-adjusted returns in healthcare and biotechnology.

The investment strategy is predicated on the understanding that biotechnology is an investible sector that is fundamentally non-discretionary, uniquely inefficient, and disproportionately requires specific scientific and clinical domain expertise.

The firm is focused on identifying long-term secular, economic, and scientific trends and then establishing discrete public equity, derivative, and opportunistic private equity investments to best execute on these ideas.